See more : PacRay International Holdings Limited (1010.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Tarsons Products Limited (TARSONS.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tarsons Products Limited, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Elsoft Research Berhad (0090.KL) Income Statement Analysis – Financial Results
- African Gold Acquisition Corporation (AGAC) Income Statement Analysis – Financial Results
- Sino Land Company Limited (SNLAF) Income Statement Analysis – Financial Results
- West Shore Bank Corp. (WSSH) Income Statement Analysis – Financial Results
- LMS Compliance Ltd. (LMS.SI) Income Statement Analysis – Financial Results
Tarsons Products Limited (TARSONS.BO)
About Tarsons Products Limited
Tarsons Products Limited engages in the manufacturing and trading of plastic laboratory products and scientific instruments in India and internationally. The company's products include disposable plastic labware, centrifuge ware, cryo labware, liquid handling systems, and instruments; and bottles, carboys, measuring cylinder, cell culture products, electrophoresis, microscopy and microbiology products, vacuum desiccators, mini coolers, cryo boxes, utilities, test tube racks, PCR products, pipette tips, petri dish, centrifuge tubes, cryo vials, pasteur pipettes, and other products. Its products are used in molecular biology, cell culture, genomics, proteomics, and immunology. Tarsons Products Limited was incorporated in 1983 and is headquartered in Kolkata, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.96B | 2.81B | 2.99B | 2.28B | 1.75B | 1.78B |
| Cost of Revenue | 942.93M | 782.40M | 800.64M | 742.80M | 585.57M | 624.36M |
| Gross Profit | 2.02B | 2.03B | 2.19B | 1.54B | 1.16B | 1.15B |
| Gross Profit Ratio | 68.19% | 72.19% | 73.24% | 67.41% | 66.54% | 64.86% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 450.62M | 33.18M | 26.69M | 21.16M | 21.67M | 41.74M |
| Selling & Marketing | 38.13M | 42.96M | 20.45M | 20.70M | 40.43M | 29.12M |
| SG&A | 488.75M | 76.14M | 47.14M | 41.86M | 62.10M | 70.86M |
| Other Expenses | 0.00 | 690.00K | 720.00K | 2.75M | 1.25M | 1.75M |
| Operating Expenses | 488.75M | 986.31M | 849.68M | 612.48M | 592.80M | 537.24M |
| Cost & Expenses | 1.39B | 1.77B | 1.65B | 1.36B | 1.18B | 1.16B |
| Interest Income | 16.47M | 28.94M | 13.14M | 2.92M | 4.05M | 2.25M |
| Interest Expense | 100.17M | 43.86M | 39.75M | 27.21M | 57.71M | 72.06M |
| Depreciation & Amortization | 404.03M | 285.09M | 219.61M | 136.62M | 141.70M | 145.64M |
| EBITDA | 1.11B | 1.42B | 1.61B | 1.09B | 734.06M | 776.38M |
| EBITDA Ratio | 37.56% | 50.24% | 53.77% | 47.70% | 41.75% | 43.52% |
| Operating Income | 1.57B | 1.03B | 1.32B | 908.62M | 560.22M | 576.72M |
| Operating Income Ratio | 52.97% | 36.65% | 44.14% | 39.87% | 32.02% | 32.46% |
| Total Other Income/Expenses | -962.34M | -660.33M | -637.84M | 15.72M | -40.10M | -56.94M |
| Income Before Tax | 607.68M | 1.09B | 1.35B | 924.34M | 531.33M | 558.25M |
| Income Before Tax Ratio | 20.50% | 38.64% | 45.12% | 40.56% | 30.37% | 31.42% |
| Income Tax Expense | 181.28M | 280.06M | 343.25M | 235.64M | 126.02M | 168.67M |
| Net Income | 426.40M | 807.14M | 1.01B | 688.70M | 405.31M | 389.58M |
| Net Income Ratio | 14.39% | 28.69% | 33.65% | 30.22% | 23.16% | 21.93% |
| EPS | 8.01 | 15.17 | 19.46 | 13.43 | 7.94 | 7.24 |
| EPS Diluted | 8.01 | 15.17 | 19.46 | 13.43 | 7.75 | 7.24 |
| Weighted Avg Shares Out | 53.23M | 53.21M | 51.74M | 51.28M | 51.02M | 53.84M |
| Weighted Avg Shares Out (Dil) | 53.21M | 53.21M | 51.74M | 51.28M | 55.10M | 53.84M |
Source: https://incomestatements.info
Category: Stock Reports